Trauma, surgery, burn injury, sepsis, prolonged bed rest, cancer, and AIDS are examples of catabolic states that can lead to a significant loss of lean body tissues and skeletal muscle. The physiologic stresses associated with these catabolic conditions can impair immune function, alter drug response, and delay the recovery process. Although enhanced nutritional supplementation is a mainstay for treating tissue wasting in these conditions, it is of limited effectiveness in reversing skeletal muscle protein loss or enhancing anabolism in lean body tissues. The use of anabolic hormones such as Growth Hormone (GH) or Insulin-Like Growth Factor 1 (IGF-1) to limit lean body wasting and preserve muscle mass in these conditions has been widely investigated. This article was designed to give pharmacists and patient care professionals an overview of recent literature involving anabolic hormone treatment of tissue wasting. The use of these agents in the clinical setting may undergo significant expansion in the near future.
TisdaleM.J.Cancer cachexia: Metabolic alterations and clinical manifestations. Nutrition.1997; 13: 1–7.
2.
PrestonT., FearonI., RobertsonB.Tissue loss during severe wasting in cancer patients. In: EllisK., ed. In Vitro Body Composition Studies.London: Institute of Physical Sciences; 1987, 61–9.
3.
ChanceW.T., van LammerenF.M., ChewM.H.Alterations in plasma levels of insulin and glucagon associated with cancer anorexia. Surg Forum.1983; 34: 441–443.
4.
WojnarM.M., FanJ., FrostR.A.Alterations in the insulin-like growth factor systems in trauma patients. Am J Physiol.1995; 268: R970–77.
5.
RodgersB.D.Catabolic hormones and growth hormone resistance in acquired immunodeficiency syndrome and other catabolic states. PSEBM.1996; 212: 324–31.
6.
MatthysP., BilliauA.Cytokines and cachexia. Nutrition.1997; 13: 763–70.
7.
GoodmanM.N.Interleukin-6 induces skeletal muscle protein breakdown in rats. PSEBM.1992; 205: 182–5.
8.
GoodmanM.N.Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol.1991; 260: E727–30.
9.
ArgilesJ.M., Lopez-SoianoF.J.The role of cytokines in cancer cachexia. Med Res Rev.1999; 19: 223–48.
10.
MatthysP., DukmansR., ProostP.Anti-interferon–antibody treatment, growth of Lewis lung tumors in mice and tumor-associated cachexia. Eur J Cancer.1991; 49: 77–82.
11.
HendersonJ.T., MullenB.J., RoderJ.C.Physiological effects of CNTF-induced wasting. Cytokine.1996; 8: 784–93.
12.
InuiA.Neuropeptide Y: A key molecule in anorexia and cachexia in wasting disorders?Mol Med Today.1999; 5: 79–85.
MaltoniM., FabbriL., NanniO.Serum levels of tumor necrosis factor and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer.1997; 5: 422–3.
15.
StreatS.J., BeddoeA.H., HillG.L.Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. J Trauma.1987; 27: 262–6.
16.
KotlerD.P., TierneyA.R., FerraroR.Enteral alimentation and repletion of cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr.1991; 53: 149–54.
17.
ZieglerT.R.Strategies for attenuating protein-catabolic responses in the critically ill. Ann Rev Med.1994; 45: 459–80.
18.
GilpinD.A., BarrowR.E., RutanR.Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. Annals Surg.1994; 220: 19–24.
19.
Belcher HJCR MercerD., JudkinsK.C.Biosynthetic human growth hormone in burned patients. A pilot study. Arch Surg.1989; 15: 99–107.
20.
GoreD.C., HoneycuttD., JahoorF.Effect of exogenous growth hormone on whole-body and isolated limb protein kinetics in burned patients. Arch Surg.1991; 126: 38–43.
21.
Vara-ThorbeckR., GuerreroJ.A., RosellJ.Exogenous growth hormone: Effects on the catabolic response to surgically produced acute stress and on post-operative immune function. World J Surg.1993; 17: 530–8.
22.
VoermanH.T., von SchijndelR.J.M., GroeneveldA.B.J.Effects of recombinant human growth hormone in patients with severe sepsis. Ann Surg.1992; 216: 648–55.
23.
GaribottoG., BarrecaA., RussoEffects of recombinant human growth hormone on muscle protein turnover in hemodialysis patients. J Clin Invest.1997; 99: 97–105.
24.
WolfR.F., PearlstoneD.B., NewmanE.Growth hormone and insulin reverse new whole body and skeletal muscle protein catabolism in cancer patients. Ann Surg.1992; 216: 280–90.
25.
TakagiK., TashiroT., YamamoriH.Recombinant human growth hormone and protein metabolism of burned rats and esophagectomized patients. Nutrition.1995; 11: 22–6.
26.
BermanR.S., HarrisonL.E., PearlstoneD.B.Growth hormone alone and in combination with insulin, increases whole body and skeletal muscle protein kinetics in cancer patients after surgery. Ann Surg.1999; 229: 19–20.
27.
KrentzA.J., KosterF.T., CristDM.Anthropometric, metabolic and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquire Immune Def.1993; 6: 245–51.
28.
SchambelanM., MulliganK., GrunfeldC.Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Int Med.1996; 125: 873–82.
29.
MulliganK., TaiV.W., SchambelanM.Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus associated wasting: A clinical research enter study. J Clin Endocrinol Metabol.1998; 83: 1542–7.
30.
PatonN.I., NewtonP.J., SharpstoneD.R.Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS.1999; 13: 1195–202.
31.
FangC.H., LiB.G., WangJ.J.Insulin-like growth factor 1 stimulates protein synthesis and inhibits protein breakdown in muscle from burned rats. J Parent Ent Nutr.1997; 21: 245–51.
32.
TashiroT., SugiuraT., MorishimaY.Effect of IGF-I on protein metabolism in burned rats. J Parent Ent Nutr.1999; 23: S93–97.
33.
NgE.H., RockC.S., LazarusD.D.Insulin-like growth factor 1 preserves lean tissue mass in cancer cachexia. Am J Physiol.1992; 263: R426–31.
HerndonD.N., RamzyP.I., DebRoyM.A.Muscle protein catabolism after severe burn: Effects of IGF-1/IGFBP-3 treatment. Ann Surg.1999; 229: 713–20.
36.
WolfS.E., BarrowR.E., HerndonD.N.Growth hormone and IGF-1 therapy in the hypercatabolic patient. Bal Clin Endocrinol Metabol.1996; 10: 447–63.
37.
KupferS.R., UnderwoodL.E., BaxterR.C.Enhancement of the anabolic effects of growth hormone and insulin-like growth factor 1 by use of both agents simultaneously. Clin Invest.1993; 91: 391–6.
38.
MeyerN.A., BarrowR.E., HerndonD.N.Combined insulin-like growth factor 1 and growth hormone improve weight loss and wound healing in burned rats. J Trauma.1996; 41: 1008–12.
39.
Bernesik, NinnisR., GirardJ.Effects of insulin-like growth factor 1 combined with growth hormone on glucocorticoidinduced whole-body protein catabolism in man. J Clin Endocrinol Metabol.1997; 82: 2528–34.
40.
NguyenB.Y., ClericiM., VenzonD.J.Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS.1998; 12: 895–904.
41.
WatersD., DanskaJ., HardyK.Recombinant human growth hormone, insulin-like growth factor 1 and combination therapy in AIDS-associated wasting. Ann Int Med.1996;125: 865–72.
42.
EllisK.J., LeeP.P., PivarnitzJ.M.Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor 1 and growth hormone. J Clin Endocrinol Metabol.1996; 81: 3033–8.
43.
EllisK.J., LeeP.D.K., PivarnikJ.M.Body composition of HIV/AIDS males: Effects of treatment with insulin-like growth actor 1 and growth hormone. Appl Radiat Isot.1998; 49: 653–5.
44.
LeeP.D.K., PivarnikJ.M., BukarJ.G.A randomized, placebo-controlled trial of combined insulin-like growth factor 1 and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metabol.1996; 81: 2968–75.
45.
McNurlanM.A., GarlickP.J., SteigbigelR.T.Responsiveness of muscle protein synthesis to growth hormone administration I HIV-infected individuals declines with disease severity. J Clin Invest.1997; 100: 2125–32.
46.
YuH., BerkelH.Insulin-like growth factors and cancer. J LA State Med Soc.1999; 151: 218–23.
47.
ConteP.F., GardinG., PronzantoP.In vivo manipulation of human breast cancer growth by estrogen and growth hormone: kinetics and clinical results. J Steroid Biochem and Mol Biol.1990; 37: 1103–8.
48.
ChanJ.M., StampferM.J., GiovannucciPlasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science.1998; 279: 563–6.
49.
HankinsonS.E., WillettW.C., ColditzG.A.Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet.1998; 351: 1393–6.
